Cyclacel Pharmaceuticals Inc.

Cyclacel Pharmaceuticals Inc. is a biopharmaceutical company developing oral therapies that target the various phases of cell-cycle control for the treatment of cancer and other serious diseases. Sapacitabine (oral capsules) is in the SEAMLESS phase 3 trial, which is being conducted under a special protocol assessment with the FDA as a front-line treatment of acute myeloid leukemia (AML) in the elderly. There are phase 2 studies for AML, myelodysplastic syndromes (MDS) and solid tumors, including lung cancer. Investigator-led studies include a phase 2/3 study comparing sapacitabine to low-dose cytarabine as front-line treatment for elderly patients with AML or high-risk MDS unfit for intensive chemotherapy, and a phase 2 study in chronic lymphocytic leukemia is in progress.